# CutisPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cutispharma

- Industry: Pharmaceuticals
- Headquarters: Wilmington, US
- Website: www.cutispharma.com
- Total disclosed funding: $20M
- Latest round: Series A (Dec 30, 2014)
- Investors on record: 1

## About

CutisPharma, Inc. is a pharmaceutical company focused on developing and commercializing innovative formulations and delivery systems for dermatological and other medical conditions.CutisPharma, Inc. specializes in pharmaceutical formulations and is headquartered in Wilmington, US. Founded in 1998, the company has undergone strategic pivots to enhance its product offerings. Richard Blackburn serves as CEO. The company has conducted a total of 4 deals, with its latest funding round being a Secondary Buyout, raising USD 69.90 mn from NovaQuest Capital Management, matching the total amount raised to USD 69.90 mn.CutisPharma, Inc. provides specialized pharmaceutical products aimed at dermatological applications. Its offerings include innovative formulations that improve medication delivery and patient compliance. The company caters to healthcare providers and patients, focusing on effective treatment solutions for skin conditions and related ailments, with a strong emphasis on meeting specific medical needs.CutisPharma, Inc. generates revenue primarily through the sale of its specialized pharmaceuticals, engaging clients such as hospitals and pharmacies. Revenue is driven by a combination of direct sales and distribution agreements, facilitating access to its unique formulations in the healthcare market.Looking ahead, CutisPharma, Inc. is focused on expanding its product line, with plans to launch new formulations within the next 12 months. The company aims to penetrate new markets in Europe and Asia by 2025, utilizing recent funding from the Secondary Buyout to support product development and market entry initiatives. Consilium Partners' acquisition of CutisPharma, Inc. aligns with its strategic growth objectives.

## Funding rounds

- Series A, Dec 30, 2014, $20M — Ampersand

## Investors

- Ampersand (https://capitalatlas.ai/funds/ampersand) — Series A